JAMA Oncology has just published data from the Zai Lab‘s Phase 3 PRIME study, highlighting the positive outcomes of ZEJULA (niraparib) as a first-line maintenance therapy for Chinese patients with advanced ovarian cancer. The study reveals that ZEJULA significantly prolongs progression-free survival and reduces the risk of disease progression or death by 55%. These findings offer hope for improved outcomes in a…
